conducted a retrospective cohort study and found that there was a significantly lower risk of HHF in patients with T2DM, overweight/obesity, and HFpEF receiving GLP-1 RA plus SGLT2i therapy compared with the SGLT2i-only therapy, suggesting a potential incremental benefit of GLP-1 RA [81]
Were not changing what works
That makes it one of the most recent and promising tools available for patients who want medical support for weight loss
In addition, Ex-4 provides neuroprotection against ischemia-induced damage in the hippocampus by downregulating hypoxia-inducible factor-1 and modulating apoptosis through the increased B-cell lymphoma 2 (Bcl-2)/Bcl-2-associated X-protein (Bax) ratio, which is mediated by the GLP-1 receptor [48]
No concerns here
For instance, one study reviewing data from Wegovy trials revealed that alopecia, a medical term for hair loss, was reported in a small percentage of participants, slightly higher than those on a placebo